

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 174 440 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
23.01.2002 Bulletin 2002/04

(21) Application number: **00202597.1**

(22) Date of filing: **19.07.2000**

(51) Int Cl.7: **C07K 16/28**, G01N 33/577,
G01N 33/569, A61K 39/395,
C12N 15/13, C12N 1/21,
A61P 31/00, A61P 35/00,
A61P 37/00

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(71) Applicant: **U-BiSys B.V.**
3584 CX Utrecht (NL)

(72) Inventors:
• **Logtenberg, Ton**
3433 CH Nieuwegein (NL)

• **Cilenti, Lucia**
00183 Roma (IT)

(74) Representative: **Prins, Adrianus Willem et al**
Vereenigde, Nieuwe Parklaan 97
2587 BN Den Haag (NL)

(54) **A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment**

(57) The present invention relates to antibodies and other binding molecules comprising a specificity for a selectively expressed CD38 epitope. Using a binding molecule of the invention it is, among others, possible to selectively mark a subset of CD38 expressing cells. An antibody or binding molecule of the invention is ca-

pable of binding to malignant B cells in a host thereby at least in part eliminating such malignant B cells from the body of the host. The invention among others provides pharmaceutical compositions, binding molecules, nucleic acids encoding binding molecules of the invention and gene delivery vehicles comprising said nucleic acid.

EP 1 174 440 A1